Nothing Special   »   [go: up one dir, main page]

DK3093345T3 - Baculovirusvektorer omfattende gentagne kodende sekvenser med differentielle foretrukne kodoner - Google Patents

Baculovirusvektorer omfattende gentagne kodende sekvenser med differentielle foretrukne kodoner Download PDF

Info

Publication number
DK3093345T3
DK3093345T3 DK16176100.2T DK16176100T DK3093345T3 DK 3093345 T3 DK3093345 T3 DK 3093345T3 DK 16176100 T DK16176100 T DK 16176100T DK 3093345 T3 DK3093345 T3 DK 3093345T3
Authority
DK
Denmark
Prior art keywords
coding sequences
baculovirus vectors
vectors including
including repeated
repeated coding
Prior art date
Application number
DK16176100.2T
Other languages
English (en)
Inventor
Andrew Christian Bakker
Wilhelmus Theodorus Johannes Maria Christiaan Hermens
Original Assignee
Uniqure Ip Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniqure Ip Bv filed Critical Uniqure Ip Bv
Application granted granted Critical
Publication of DK3093345T3 publication Critical patent/DK3093345T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/864Parvoviral vectors, e.g. parvovirus, densovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14041Use of virus, viral particle or viral elements as a vector
    • C12N2710/14044Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • C12N2750/14152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/50Vectors for producing vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK16176100.2T 2007-07-26 2008-07-25 Baculovirusvektorer omfattende gentagne kodende sekvenser med differentielle foretrukne kodoner DK3093345T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95208107P 2007-07-26 2007-07-26
EP07113257 2007-07-26
EP08779058.0A EP2173888B1 (en) 2007-07-26 2008-07-25 Baculoviral vectors comprising repeated coding sequences with differential codon biases

Publications (1)

Publication Number Publication Date
DK3093345T3 true DK3093345T3 (da) 2019-06-24

Family

ID=38753583

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16176100.2T DK3093345T3 (da) 2007-07-26 2008-07-25 Baculovirusvektorer omfattende gentagne kodende sekvenser med differentielle foretrukne kodoner
DK08779058.0T DK2173888T3 (da) 2007-07-26 2008-07-25 Baculovirusvektorer omfattende gentagne kodende sekvenser med differentielle foretrukne kodoner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08779058.0T DK2173888T3 (da) 2007-07-26 2008-07-25 Baculovirusvektorer omfattende gentagne kodende sekvenser med differentielle foretrukne kodoner

Country Status (20)

Country Link
US (5) US8697417B2 (da)
EP (3) EP3093345B8 (da)
JP (2) JP5634262B2 (da)
KR (1) KR101597695B1 (da)
CN (1) CN101868547B (da)
AU (1) AU2008279883B2 (da)
BR (1) BRPI0814459B1 (da)
CA (1) CA2694406C (da)
DK (2) DK3093345T3 (da)
EA (1) EA022169B1 (da)
ES (1) ES2602585T3 (da)
HK (1) HK1143185A1 (da)
HU (1) HUE029744T2 (da)
IL (1) IL203535A (da)
MX (1) MX2010000944A (da)
NZ (1) NZ582881A (da)
PL (2) PL2173888T3 (da)
PT (1) PT2173888T (da)
SI (2) SI2173888T1 (da)
WO (1) WO2009014445A2 (da)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3093345B8 (en) * 2007-07-26 2019-07-24 UniQure IP B.V. Baculoviral vectors comprising repeated coding sequences with differential codon biases
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
EP3792348A3 (en) 2010-03-11 2021-06-23 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
IT1400425B1 (it) 2010-06-08 2013-05-31 Amsterdam Molecular Therapeutics Bv Modified snrnas for use in therapy.
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
EP3060669A1 (en) 2013-10-24 2016-08-31 uniQure IP B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
KR102572449B1 (ko) 2014-03-10 2023-08-31 유니큐어 아이피 비.브이. 곤충 세포에서 생산된 더욱 향상된 aav 벡터
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
RU2020109343A (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
RU2719192C2 (ru) 2014-11-14 2020-04-17 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
CA2967367C (en) 2014-11-14 2023-05-16 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP4219742A1 (en) 2014-11-28 2023-08-02 uniQure IP B.V. Dna impurities in a composition comprising a parvoviral virion
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
PL3237618T3 (pl) 2014-12-24 2019-09-30 Uniqure Ip B.V. Supresja genu huntingtyny indukowana rnai
AU2017254652B2 (en) 2016-04-21 2022-12-01 Virovek, Inc. AAV production in insect cells, methods and compositions therefor
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109831916B (zh) 2016-05-18 2023-07-21 沃雅戈治疗公司 治疗亨廷顿氏舞蹈病的组合物和方法
CA3024448A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Modulatory polynucleotides
KR20230161535A (ko) 2016-07-26 2023-11-27 바이오마린 파머수티컬 인크. 신규 아데노-관련 바이러스 캡시드 단백질
AU2017315679B2 (en) 2016-08-23 2023-12-14 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CA3045551A1 (en) 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法
AU2018261790B2 (en) 2017-05-05 2024-10-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
IL271957B2 (en) 2017-07-10 2024-02-01 Uniqure Ip Bv Means and methods for AAV-based gene therapy
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
AU2018394287B2 (en) 2017-12-29 2024-09-26 Uniqure Ip B.V. Modified viral vectors and methods of making and using the same
HUE062774T2 (hu) 2018-01-17 2023-12-28 Meiragtx Uk Ii Ltd Módosított rAAV kapszidfehérje génterápiához
EP3793616A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US12060567B2 (en) 2018-06-13 2024-08-13 Voyager Therapeutics, Inc. Engineered untranslated regions (UTR) for AAV production
US20210254103A1 (en) 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
SG11202100704PA (en) 2018-07-24 2021-02-25 Voyager Therapeutics Inc Systems and methods for producing gene therapy formulations
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
CA3112007A1 (en) 2018-09-12 2020-03-19 Uniqure Ip B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd
WO2020061418A1 (en) * 2018-09-20 2020-03-26 Tallgrass Biologics L.L.C. Treatment and control of colony collapse disorder
CN109295172A (zh) * 2018-09-26 2019-02-01 浙江海洋大学 大黄鱼清道夫受体家族基因的密码子偏好性分析方法
US20210395776A1 (en) 2018-09-28 2021-12-23 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
CA3115248A1 (en) 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CA3116701A1 (en) 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. Expression vectors for large-scale production of raav in the baculovirus/sf9 system
WO2020104480A1 (en) 2018-11-19 2020-05-28 Uniqure Biopharma B.V. Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
WO2020104435A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. A companion diagnostic to monitor the effects of gene therapy
US20200199625A1 (en) 2018-11-19 2020-06-25 Uniqure Ip B.V. RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3
WO2020104469A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. Method and means to deliver mirna to target cells
MX2021008542A (es) 2019-01-18 2021-11-12 Voyager Therapeutics Inc Métodos y sistemas para la producción de partículas de aav.
EP3962536A1 (en) 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
KR20220081971A (ko) 2019-07-15 2022-06-16 메이라지티엑스 유케이 Ii 리미티드 관절염 질환 치료용 변형된 aav 캡시드 단백질
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021041375A1 (en) * 2019-08-26 2021-03-04 Rootpath Genomics, Inc. Compositions and methods for producing adeno-associated viral vectors
EP4031148A1 (en) 2019-09-16 2022-07-27 uniQure IP B.V. Targeting misspliced transcripts in genetic disorders
IL295747A (en) 2020-02-21 2022-10-01 Akouos Inc Preparations and methods for the treatment of hearing impairment that is not related to age in humans
WO2021195491A2 (en) * 2020-03-26 2021-09-30 Asklepios Biopharmaceutical, Inc. Inducible promoter for viral vector production
JP2023519502A (ja) 2020-04-02 2023-05-11 ユニキュアー バイオファーマ ビー.ブイ. Aav生成のための二重二官能基ベクター
CN115867647A (zh) 2020-04-02 2023-03-28 优尼科生物制药有限公司 新型细胞系
CA3174872A1 (en) 2020-04-07 2021-10-14 Sander Jan Hendrik Van Deventer Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof
BR112022020753A2 (pt) 2020-04-15 2022-12-20 Voyager Therapeutics Inc Compostos de ligação a tau
CN117120619A (zh) 2020-07-27 2023-11-24 沃雅戈治疗公司 用于治疗与葡萄糖神经酰胺酶β缺陷相关的神经病症的组合物和方法
WO2022026410A2 (en) 2020-07-27 2022-02-03 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN115427561B (zh) 2021-03-09 2024-06-04 辉大(上海)生物科技有限公司 工程化CRISPR/Cas13系统及其用途
WO2022214635A1 (en) 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
CA3219847A1 (en) 2021-06-02 2022-12-08 Sander Jan Hendrik Van Deventer Adeno-associated virus vectors modified to bind high-density lipoprotein
EP4347798A2 (en) 2021-06-02 2024-04-10 uniQure biopharma B.V. Insect cell production of parvoviral vectors with modified capsid proteins
EP4359525A1 (en) 2021-06-21 2024-05-01 uniQure biopharma B.V. Gene constructs for silencing alpha-synuclein and uses thereof
WO2022268811A1 (en) 2021-06-21 2022-12-29 Uniqure Biopharma B.V. Improved lysis procedures
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
EP4392434A1 (en) 2021-08-26 2024-07-03 uniQure biopharma B.V. Insect cell-produced high potency aav vectors with cns-tropism
WO2023091949A2 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2023147374A2 (en) 2022-01-25 2023-08-03 Voyager Therapeutics, Inc. Baculovirus expression system
CN114703203B (zh) * 2022-02-11 2024-08-06 上海渤因生物科技有限公司 杆状病毒载体及其用途
WO2023198745A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of apoe
WO2023198702A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of c9orf72
WO2023198662A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Novel systems for nucleic acid regulation
WO2023198663A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of snca
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024163012A1 (en) 2023-02-02 2024-08-08 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2024218190A1 (en) 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Generation of adeno-associated virus capsid libraries for insect cells
WO2024218192A1 (en) 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
WO2024218204A1 (en) 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Gene delivery vehicles comprising rna and antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5871974A (en) * 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
NZ308772A (en) 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
FR2774699B1 (fr) 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
WO2001000220A2 (en) 1999-06-24 2001-01-04 The University Of British Columbia Lipoprotein lipase (lpl) variant therapeutics
KR20020059370A (ko) * 1999-08-20 2002-07-12 추후보정 융합 라이브러리의 제작 및 사용을 위한 방법 및 조성물
WO2001068888A2 (en) * 2000-03-14 2001-09-20 Neurologix, Inc. Production of chimeric capsid vectors
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP1572893B1 (en) 2001-11-09 2009-01-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES Production of adeno-associated virus in insect cells
CA2369985A1 (en) * 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
US20040063188A1 (en) * 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
DE10260805A1 (de) 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
US20070275449A1 (en) * 2003-10-15 2007-11-29 Vector Gene Technology Company Ltd. Method for Large-Scale Production, Isolation, Purification and the Uses of Multi-Type Recombinant Adeno-Associated Virus Vectors
WO2005072364A2 (en) 2004-01-27 2005-08-11 University Of Florida A modified baculovirus expression system for production of pseudotyped raav vector
DK1776460T3 (da) 2004-08-03 2010-04-12 Geneart Ag Fremgangsmåde til modulering af genekspression ved ændring af CpG-indholdet
DK1945779T3 (da) 2005-10-20 2013-06-03 Uniqure Ip Bv Forbedrede AAV vektorer frembragt i insektceller
EP1981548A4 (en) * 2006-01-20 2010-03-24 Univ North Carolina ENHANCED PRODUCTION OF INFECTIOUS VECTORS OF PARVOVIRUS IN INSECT CELLS
US8512981B2 (en) 2006-06-21 2013-08-20 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV
EP3093345B8 (en) * 2007-07-26 2019-07-24 UniQure IP B.V. Baculoviral vectors comprising repeated coding sequences with differential codon biases

Also Published As

Publication number Publication date
HUE029744T2 (en) 2017-04-28
EP2173888B1 (en) 2016-08-17
US11306291B2 (en) 2022-04-19
US20190203183A1 (en) 2019-07-04
ES2602585T3 (es) 2017-02-21
US8697417B2 (en) 2014-04-15
CN101868547A (zh) 2010-10-20
DK2173888T3 (da) 2016-11-28
EP3561063A1 (en) 2019-10-30
US20140186926A1 (en) 2014-07-03
SI3093345T1 (sl) 2019-08-30
EA022169B1 (ru) 2015-11-30
PL2173888T3 (pl) 2017-02-28
KR101597695B1 (ko) 2016-02-25
CN101868547B (zh) 2016-03-16
US10190098B2 (en) 2019-01-29
JP5634262B2 (ja) 2014-12-03
KR20100065284A (ko) 2010-06-16
CA2694406A1 (en) 2009-01-29
JP2014239686A (ja) 2014-12-25
PT2173888T (pt) 2016-11-17
AU2008279883A1 (en) 2009-01-29
US9580691B2 (en) 2017-02-28
EP2173888A2 (en) 2010-04-14
WO2009014445A2 (en) 2009-01-29
EA201070184A1 (ru) 2010-08-30
EP3093345B1 (en) 2019-04-24
BRPI0814459A2 (pt) 2014-10-21
MX2010000944A (es) 2010-08-31
BRPI0814459B1 (pt) 2023-01-24
IL203535A0 (en) 2011-07-31
AU2008279883B2 (en) 2013-12-05
JP2010534472A (ja) 2010-11-11
WO2009014445A3 (en) 2009-04-30
HK1143185A1 (zh) 2010-12-24
EP3093345A1 (en) 2016-11-16
EP3093345B8 (en) 2019-07-24
SI2173888T1 (sl) 2017-01-31
US20100261254A1 (en) 2010-10-14
IL203535A (en) 2016-02-29
CA2694406C (en) 2019-03-26
US20220251520A1 (en) 2022-08-11
PL3093345T3 (pl) 2020-03-31
US20160032254A1 (en) 2016-02-04
NZ582881A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
DK3093345T3 (da) Baculovirusvektorer omfattende gentagne kodende sekvenser med differentielle foretrukne kodoner
BRPI0918426A2 (pt) códigos multi-coloridos
DK2115143T3 (da) Buttiauxella sp.-fytasevarianter med ændrede egenskaber
ZA201009013B (en) Bronchoalveolar lavage catheter assembly
DK3484076T3 (da) Computermæssigt effektiv konvolutionskodning med rate-matching
DE602008002445D1 (de) Poliervorrichtung
BRPI0911849A2 (pt) protetores solares
IL200353A (en) Re-viruses with tailored sequences
BRPI0816900A2 (pt) Equipamento de usuário
DE602005012822D1 (de) Nmr-hf-spulen mit aufgeteilten beweglichen kapazitätsbändern
DK2122102T3 (da) Indretning med fleksibelt forhæng
DE602008003253D1 (de) Schiebeelement
BRPI0916202A2 (pt) cabo umbilical
FI20075382L (fi) Viemäriveden välipumppaamo
DE502006003047D1 (de) Gummisleeve
HUE043953T2 (hu) Eltérõ kodonhasználatú, megismételt kódoló szekvenciákat tartalmazó bakulovírus-vektorok
GB0808017D0 (en) shRHA sequences
ES1065910Y (es) Carpa lineal
DK200700225U1 (da) Kemisk forbindelse med nyttige egenskaber
ES1068259Y (es) Celosia tubular
UY3748Q (es) Perfil
UY3747Q (es) Perfil
UA15443S (uk) Профіль
UA15442S (uk) Профіль
UA17342S (uk) Профіль